Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cambridge Cognition falls short with £6m IPO

This article was originally published in Clinica

Executive Summary

UK neuropsychological test developer Cambridge Cognition has succeeded in going public but, like many of its peers carrying out IPOs recently, has only raised a fraction of its target amount. The company raised a total of £6.4 million ($9.8 million): £5 million from the placement of new ordinary shares; and £1.4 million through the sale of existing ordinary shares, all priced at 70p each. However, Cambridge Cognition had originally hoped to bring in up to £15 million from the IPO (www.clinica.co.uk, 26 March 2013). The company, which is now listed on the London Stock Exchange's AIM market under the ticker symbol COG, has a market cap of around £11.8 million.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT100267

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel